当前位置: 首页 > 详情页

Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [2]Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [3]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing Neurosurg Inst, Beijing, Peoples R China; [4]Cangzhou Cent Hosp, Dept Neurosurg 3, Cangzhou, Peoples R China
出处:
ISSN:

关键词: glioma let-7a K-ras miRNA PTEN

摘要:
Altered expression of micro(mi)RNAs has been shown to be associated with tumorigenesis and tumor progression. The expression of phosphatase and tensin homolog (PTEN) plays an important role in glioma and is regarded as a prognostic marker of glioma patients. The goal of this study was to investigate the function of lethal (let)-7a miRNA in glioma cell lines with different PTEN phenotypes. One hundred ninety-eight glioma tissues were used to profile miRNA expression. Let-7a was shown to have lower expression in high-grade glioma than in low-grade glioma. Low expression of let-7a was correlated with poor prognosis of primary glioblastoma patients. We demonstrated that K-ras was a functional target for let-7a to induce cell cycle arrest, apoptosis, and inhibition of cell migration and invasion in vitro. Our further results showed no difference in malignancy inhibition induced by let-7a in 4 glioma cells, including U87 (PTEN null), U251 (PTEN mutant), LN229 (PTEN wild type), and LN229 (PTEN small interfering RNA). The phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways were inhibited by let-7a, and the inhibition effects had no difference in 4 glioma cells. We demonstrated that let-7a could induce suppression of glioma in vivo by generating a glioma xenograft model. Our results indicated that let-7a suppresses its target transcript K-ras and inhibits glioma malignancy independent of PTEN expression.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学 2 区 肿瘤学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 临床神经病学 1 区 肿瘤学
JCR分区:
出版当年[2011]版:
Q1 ONCOLOGY Q1 CLINICAL NEUROLOGY
最新[2023]版:
Q1 CLINICAL NEUROLOGY Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [4]Cangzhou Cent Hosp, Dept Neurosurg 3, Cangzhou, Peoples R China
通讯作者:
通讯机构: [1]Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院